Search

Michelle C Callegan

from Edmond, OK
Age ~57

Michelle Callegan Phones & Addresses

  • 616 Citation Dr, Edmond, OK 73025 (405) 715-2546
  • 1517 179Th St, Edmond, OK 73003
  • Oklahoma City, OK
  • Metairie, LA

Resumes

Resumes

Michelle Callegan Photo 1

James P Luton Professor Of Ophthalmology

View page
Location:
Oklahoma City, OK
Industry:
Higher Education
Work:
University of Oklahoma Health Sciences Center Jan 1996 - Apr 1999
Postdoctoral Fellow

University of Oklahoma Health Sciences Center Jan 1996 - Apr 1999
James P Luton Professor of Ophthalmology
Education:
Louisiana State University Health Sciences Center 1989 - 1995
Doctorates, Doctor of Philosophy, Microbiology, Immunology, Philosophy
Louisiana State University 1984 - 1988
Bachelors, Microbiology
Skills:
Cell Culture
Research
Molecular Biology
Infectious Diseases
Biochemistry
Science
Teaching
Life Sciences
Cell Biology
Pcr
Confocal Microscopy
In Vivo
Michelle Callegan Photo 2

Michelle Callegan

View page

Business Records

Name / Title
Company / Classification
Phones & Addresses
Michelle Callegan
Administrator Executive
Dean A Mc GEE Eye Institute
Offices and Clinics of Optometrists
8121 National Ave STE 407, Oklahoma City, OK 73110
(405) 733-4545
Michelle Callegan
Scientist
University of Oklahoma
College/University
660 Parrington Oval, Norman, OK 73019
(405) 325-4122

Publications

Us Patents

Treatment Of Ocular Wounds And Ulcers

View page
US Patent:
7893027, Feb 22, 2011
Filed:
Oct 22, 2007
Appl. No.:
11/975810
Inventors:
Heloise Anne Pereira - Edmond OK, US
James Chodosh - Edmond OK, US
Michelle C. Callegan - Edmond OK, US
Assignee:
The Board of Regents of the University of Oklahoma - Norman OK
International Classification:
A61K 38/16
A61K 9/00
US Classification:
514 12, 530324, 530326, 530350, 530402, 424 91
Abstract:
A method for treating ocular conditions such as bacterial keratitis, bacterial conjunctivitis, corneal ulcers and wounds, endophthalmitis, and blebitis in mammals, by using a native, synthetic, or recombinant CAP37, or effective peptide portions thereof including CAP37 peptides 20-44, 23-42, 102-122, and 120-146 and monocysteine derivatives of peptides 20-44 and 23-42. The CAP37, peptides, and peptide derivatives can also be used to store, clean, sterilize, or coat contact lenses, and may be used in media for storing mammalian corneal transplants.

Treatment And Inhibition Of Ocular Infections And Wounds By Cap37 And Cap37 Peptides

View page
US Patent:
20030206938, Nov 6, 2003
Filed:
Apr 25, 2003
Appl. No.:
10/423311
Inventors:
Heloise Pereira - Edmond OK, US
James Chodosh - Edmond OK, US
Michelle Callegan - Edmond OK, US
International Classification:
A61K038/16
A61K009/00
US Classification:
424/429000, 514/012000
Abstract:
A method for treating ocular conditions such as bacterial keratitis, bacterial conjunctivitis, corneal ulcers and wounds, endophthalmitis, and blebitis in mammals, by using a native, synthetic, or recombinant CAP37, or effective peptide portions thereof including CAP37 peptides 20-44, 23-42, 102-122, and 120-146 and monocysteine derivatives of peptides 20-44 and 23-42. The CAP37, peptides, and peptide derivatives can also be used to store, clean, sterilize, or coat contact lenses, and may be used in media for storing mammalian corneal transplants.
Michelle C Callegan from Edmond, OK, age ~57 Get Report